# Valaciclovir to Prevent Transmission of Herpes Simplex Virus

> **NCT00001649** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 180 (—)

## Conditions studied

- Herpes Simplex

## Interventions

- **DRUG:** Valaciclovir

## Key facts

- **NCT ID:** NCT00001649
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-08
- **Primary completion:** —
- **Final completion:** 2003-08
- **Target enrollment:** 180 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001649

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001649, "Valaciclovir to Prevent Transmission of Herpes Simplex Virus". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00001649. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*